TrialNet Phase 1 Study: Tolerance Using Plasmid in People with T1D 

Now enrolling adults diagnosed with T1D in the past 4 years 

TrialNet is excited to announce the launch of our first Phase 1 clinical study to test a new plasmid therapy. The study will enroll 48 adults (age 18-45) diagnosed with type 1 diabetes (T1D) in the past 4 years. 

Each November, we join the diabetes community to recognize Diabetes Awareness Month and World Diabetes Day on November 14th. This year, as TrialNet begins to celebrate 20 years, we share major research advances made possible by our incredible study participants and research teams around the world.
Identifying early stages of T1D
 

During this difficult time for families around the world, staying at home is vitally important to controlling the spread of COVID-19. And, we’re continually amazed and thankful to see all the ways families are finding ways to make a difference.

A message from TrialNet Chair Carla Greenbaum, M.D.

At TrialNet, the health and safety of our participants and research teams is always our top priority.

In a two-year study wrapping up at year's end, frozen blood samples from previous TrialNet study participants who did not receive the study drug played a starring role.

For most people, the onset of type 1 diabetes seems to occur suddenly, often resulting in a trip to the emergency room with life-threatening complications such as diabetic ketoacidosis (DKA). TrialNet is working to change that scenario.

A newly launched prevention study will test the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (st

TrialNet screening is free, quick, and now more convenient than ever. Our new in-home test kits provide everything you need to collect your or your family member’s blood sample in the comfort of your home.